1. Medtech Insight
  2. >>Archive

Single-Use, Disposable Devices Drive Growth In NPWT Market

Growth in the market for negative pressure wound therapy (NPWT) devices, which account for more than 40% of the US advanced wound care products market, will be driven in large part going forward by new, single-use disposable products, which are more convenient and cost-effective than traditional NPWT machines. Such products are finding increasing adoption for the treatment of closed surgical incisions.

Negative pressure wound therapy (NPWT) is already widely used for treating both acute and chronic wounds such as diabetic ulcers. But over the past several years, there has been growing interest in the use of NPWT for treating closed surgical incisions following standard suturing and as a substitute for a normal dressing. Much of the projected growth in this segment of the market is due to the development of single-use, disposable, and portable NPWT devices that are more convenient to use and much less costly than the bulky, reusable NPWT machines that tether to the patient.

“The thought has been that using levels of suction or negative pressure may enhance healing and may result in less complications,” says Ed Armstrong, VP of marketing for advanced wound devices at Smith & Nephew Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight